Helen Heslop, MD
The Methodist Hospital Research Institute · Baylor College of Medicine · Baylor College of Medicine/Texas Children's Hospital /Houston Methodist Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Helen Heslop, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:49 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07729397 · Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)The Methodist Hospital Research Institute · not yet recruiting · Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL) · principal investigator
- Early Ph1NCT06598332 · 5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)Baylor College of Medicine · withdrawn · Graft-Versus-Host Disease(GVHD) · principal investigator
- Ph1NCT06176690 · Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine · recruiting · CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive · principal investigator
- Ph1NCT05352828 · Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline TherapyTessa Therapeutics · active not recruiting · Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent · principal investigator
- Ph1/Ph2NCT04345601 · Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)Baylor College of Medicine · completed · Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19 · study director
- Ph1NCT04288726 · Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive LymphomasBaylor College of Medicine · active not recruiting · Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma · principal investigator
- Ph2NCT04268706 · Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)Tessa Therapeutics · active not recruiting · Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory · principal investigator
- Ph1NCT02917083 · CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)Baylor College of Medicine · recruiting · Hodgkin's Lymphoma, Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT02379520 · HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIABaylor College of Medicine · completed · Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma · principal investigator
- Ph1NCT02239861 · TAA-Specific CTLS for Solid Tumors (TACTASOM)Baylor College of Medicine · completed · Rhabdomyosarcoma · principal investigator
- Ph1NCT02065362 · TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPCBaylor College of Medicine · active not recruiting · EBV-positive Nasopharyngeal Carcinoma · principal investigator
- Ph2NCT01948180 · Cellular Immunotherapy Treatment Antigen-Directed for EBV LymphomaCell Medica Ltd · terminated · Lymphoma, Extranodal NK-T-Cell, EBV · principal investigator
- Ph1NCT01853631 · Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)Baylor College of Medicine · recruiting · Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT01570283 · ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK VirusAlloVir · completed · Viral Infection · principal investigator
- Ph1/Ph2NCT01192555 · Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk NeuroblastomaBaylor College of Medicine · active not recruiting · Neuroblastoma · principal investigator
- Ph1NCT00881920 · Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALLBaylor College of Medicine · active not recruiting · Lymphoma, Myeloma, Leukemia · principal investigator
- Ph1/Ph2NCT00711035 · Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)Baylor College of Medicine · completed · Adenovirus Infection, EBV Infection · principal investigator
- Ph1NCT00586391 · CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLBaylor College of Medicine · active not recruiting · B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia · principal investigator
- Ph1NCT00058604 · Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).Baylor College of Medicine · completed · Epstein-Barr Virus Infections, Lymphoproliferative Disorders · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- CHIMERIC T CELLS TARGETING NEUROBLASTOMAP01CA094237 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HELEN E HESLOP, CLIONA M. ROONEY · fiscal years 2002 to 2017Named on NCT02065362
- Improving the safety and efficacy of cell therapiesU54HL081007 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI MALCOLM K. BRENNER · fiscal years 2005 to 2009Named on NCT00711035
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in neuroblastoma.